Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

Running, not enrolling · Phase 3

Conditions studied: NSCLC

In brief

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

Key facts

Study ID

NCT05687266

Run by

AstraZeneca

People needed

1350

Starts

2022-12-29

Expected to finish

2027-11-01

Last updated by the study team

2026-04-22

Who can join

Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Hefei, China
• Research Site — Jinan, China
• Research Site — Kunming, China
• Research Site — Lanzhou, China
• Research Site — Liuzhou, China
• Research Site — Shandong, China
• Research Site — Shanghai, China
• Research Site — Shanghai, China
• Research Site — Shanghai, China
• Research Site — Shantou, China
• Research Site — Shenyang, China
• Research Site — Shenzhen, China
• Research Site — Taiyuan, China
• Research Site — Tianjin, China
• Research Site — Wenzhou, China
• Research Site — Wuhan, China
• Research Site — Wuhan, China
• Research Site — Xiamen, China
• Research Site — Yangzhou, China
• Research Site — Zhengzhou, China
• Research Site — Brest, France
• Research Site — Créteil, France
• Research Site — Gleizé, France
• Research Site — Montpellier, France
• Research Site — Guangzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.